Matthew Kapusta Sells 21,082 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 21,082 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total value of $952,063.12. Following the completion of the sale, the chief executive officer directly owned 519,227 shares of the company’s stock, valued at approximately $23,448,291.32. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Price Performance

Shares of NASDAQ:QURE traded up $0.05 on Tuesday, reaching $41.41. 2,218,137 shares of the company were exchanged, compared to its average volume of 2,726,536. The company has a 50-day moving average of $31.01 and a 200-day moving average of $24.02. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of -11.90 and a beta of 0.90. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. Equities analysts forecast that uniQure N.V. will post -3.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in QURE. Torren Management LLC purchased a new position in uniQure in the 4th quarter valued at about $28,000. IFP Advisors Inc purchased a new stake in shares of uniQure during the fourth quarter worth about $48,000. Smartleaf Asset Management LLC acquired a new position in shares of uniQure in the fourth quarter valued at approximately $48,000. CIBC Private Wealth Group LLC purchased a new position in shares of uniQure during the third quarter valued at approximately $50,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in uniQure by 42.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 906 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. The Goldman Sachs Group lifted their price objective on uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a report on Thursday, June 18th. Stifel Nicolaus set a $28.00 price target on uniQure in a research note on Tuesday, May 5th. Mizuho boosted their price objective on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a research note on Wednesday, June 17th. Finally, Royal Bank Of Canada lifted their target price on shares of uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Twelve investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $64.17.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.